Orthogon Therapeutics is developing a first-in-class oral antiviral program focused on BK polyomavirus with a lead candidate that targets the VP1 capsid protein. The company’s approach aims to deliver antiviral activity at the site of viral replication to provide sustained control across BK variants and related polyomaviruses. Orthogon has analyzed hundreds of patient-derived BK virus sequences, finding substantial diversity in antibody-binding regions and replication beyond circulating antibodies, which it cites to justify a small-molecule strategy. Beyond BK virus, the company is advancing programs against JC virus and other transplant-associated infections using its proprietary drug discovery platform. Financially, Orthogon has now raised $36 million in total capital following the $11 million follow-on financing reported in the article.

Total raised

$27M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2026